Frankfurt, Germany

Jan Oehme

This inventor holds 1 USPTO granted patent and 2 EPO patents. Top assignee: Sanofi-A Ventis Deutschland Gmbh. Active years: 2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jan Oehme. Retrieved from https://idiyas.com/inventor/jan-oehme

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2018

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jan Oehme: Innovator in Pharmaceutical Chemistry

Introduction

Jan Oehme is a notable inventor based in Frankfurt, Germany. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of processes for drug synthesis. His work has led to advancements in the production of important pharmaceutical compounds.

Latest Patents

Jan Oehme holds a patent for a process for the preparation of ramipril. This patent describes an enantioselective process for the production of (2S,3aS,6aS)-cyclopenta[b]pyrrole-2-carboxylic acid and its conversion into ramipril. This innovation is crucial for the efficient synthesis of this important medication.

Career Highlights

Throughout his career, Jan Oehme has worked with prominent companies in the pharmaceutical industry. He has been associated with Sanofi-Aventis Deutschland GmbH and Zentiva K.S. His experience in these organizations has allowed him to refine his skills and contribute to significant projects in drug development.

Collaborations

Jan Oehme has collaborated with several professionals in his field. Notable coworkers include Gerhard Kretzschmar and Kai Rossen. These collaborations have enhanced his research and development efforts, leading to successful outcomes in his projects.

Conclusion

Jan Oehme is a distinguished inventor whose work in pharmaceutical chemistry has made a lasting impact. His innovative processes and collaborations with industry leaders highlight his commitment to advancing drug synthesis. His contributions continue to influence the field positively.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…